With a standardized full course of chemotherapy, only 50% to 60% of patients ultimately achieve long-term disease-free survival.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin’s lymphoma, accounting for 35% to 40% of cases. Most are primary, but can also progress or transform from inert lymphomas.The 2016 edition of WHO staging further classifies diffuse large B-cell lymphoma into germinal center versus activated cell type based on cellular origin.
After anthracycline-based chemotherapy (adriamycin + vincristine + cyclophosphamide + dexamethasone), remission is achieved in more than 70% of patients, but ultimately only 50% to 60% of patients achieve long-term disease-free survival.
In recent years, with the use of new drugs, such as anti-CD20 monoclonal antibodies, or the administration of intense chemotherapy to patients with a poor prognosis, the prognosis of such patients has significantly improved.
Specific disease diagnosis and treatment should be under the supervision of a physician.